Zelira TherapeuticsZLDAF 10 ROA % is -134.41% as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 10/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,419 Biotechnology companies, Zelira Therapeutics ranks worse than 86.89% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Zelira Therapeutics's annualizedNet Income for the quarter that ended in Jun. 2025 was $-1.58 Mil.
Zelira Therapeutics's average Total Assets over the quarter that ended in Jun. 2025 was $1.18 Mil. Therefore, Zelira Therapeutics's annualized ROA % for the quarter that ended in Jun. 2025 was -134.41%.
The historical rank and industry rank for Zelira Therapeutics's ROA % or its related term are showing as below:
ZLDAF'
s ROA % Range Over the Past 10 Years
Min: -362.5 Med: -54.15 Max: -15.57
Current: -122.72
During the past 13 years, Zelira Therapeutics's highest ROA % was -15.57%. The lowest was -362.50%. And the median was -54.15%.
ZLDAF's ROA % is ranked worse than 86.89% of 1419
companies
in the Biotechnology industry
Industry Median: -32.84
vs ZLDAF: -122.72
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Jun. 2025) net income data. The Revenue data used here is two times the semi-annual (Jun. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Zelira Therapeutics ROA % Related Terms
Zelira Therapeutics ROA % Historical Data
* Premium members only.
The historical data trend for Zelira Therapeutics's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zelira Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelira Therapeutics ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's ROA % distribution charts can be found below:
* The bar in red indicates where Zelira Therapeutics's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Zelira Therapeutics (ZLDAF) has a ROA % of -134.41% as of Jun. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Zelira Therapeutics and its competitors. According to the industry distribution chart, Zelira Therapeutics ranks #1233 out of 1419 companies in the Biotechnology industry, placing it in the top 86.9%.
Is Zelira Therapeutics' ROA % too high?
Zelira Therapeutics' current ROA % is -134.41%. Based on the distribution chart, Zelira Therapeutics ranks #1233 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zelira Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' ROA % compare to MTNB and SXTP?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #1233 out of 1419 companies for ROA %. This places Zelira Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current ROA % is -134.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zelira Therapeutics (ZLDAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.35 — trading 337.5% above its estimated fair value. The current ROA % is -134.41%. Zelira Therapeutics' overall GF Score™ is 10/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current ROA % is -134.41% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?
Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued.
The current stock price of $0.35 is trading 337.5% above its estimated GF Value™ of $0.08.
GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.
Key valuation signals for ZLDAF:
ROA %: -134.41%
GF Value™: $0.08 vs. price of $0.35 (337.5% above fair value)
No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
10GF Score
Get the complete analysis for ZLDAF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDAF has been successfully added to your 
